Mater Private Hospital

The Oncology department at Mater Private Hospital is also exploring heart conditions, concentrating on patients with heart failure with mildly reduced or preserved ejection fraction and systemic inflammation. The trials seek to evaluate a novel anti‑inflammatory biologic to lower cardiovascular mortality and heart‑failure events.

• Inflammation‑driven heart failure
• Monthly subcutaneous biologic therapy
• Risk reduction of cardiovascular death
• Integration with standard heart‑failure care

With 14 investigators overseeing four active studies, the site in Dublin contributes valuable data on managing heart failure in the European research community.

The oncology unit at Mater Private Hospital conducts multiple studies on prostate adenocarcinoma and various forms of breast cancer, including early‑stage ER+/HER2‑ disease. These trials aim to test new hormonal agents and targeted therapies that can delay progression, reduce metastasis, and prevent recurrence.

• Castration‑naïve metastatic prostate cancer
• Oral selective androgen receptor inhibitor
• Selective estrogen receptor degraders
• Combination endocrine therapy with CDK4/6 inhibition

Across four trials, 14 investigators are evaluating innovative treatments to improve outcomes for patients with these cancers, reinforcing the site’s role in advancing cancer care in Ireland and Europe.